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ABSTRACT 
Toxicokinetic modeling is a useful tool to describe or predict the behavior of a chemical 
agent in the human or animal organism. A general model based on four compartments was 
developed in a previous study in order to quantify the effect of human variability on a wide 
range of biological exposure indicators.     
The aim of this study was to adapt this existing general toxicokinetic model to three organic 
solvents, which were methyl ethyl ketone, 1-methoxy-2-propanol and 1,1,1,-trichloroethane, 
and to take into account sex differences. We assessed in a previous human volunteer study the 
impact of sex on different biomarkers of exposure corresponding to the three organic solvents 
mentioned above. Results from that study suggested that not only physiological differences 
between men and women but also differences due to sex hormones levels could influence the 
toxicokinetics of the solvents. In fact the use of hormonal contraceptive had an effect on the 
urinary levels of several biomarkers, suggesting that exogenous sex hormones could influence 
CYP2E1 enzyme activity. These experimental data were used to calibrate the toxicokinetic 
models developed in this study. 
Our results showed that it was possible to use an existing general toxicokinetic model for 
other compounds. In fact, most of the simulation results showed good agreement with the 
experimental data obtained for the studied solvents, with a percentage of model predictions 
that lies within the 95% confidence interval varying from 44.4 to 90 %. Results pointed out 
that for same exposure conditions, men and women can show important differences in urinary 
levels of biological indicators of exposure. Moreover, when running the models by simulating 
industrial working conditions, these differences could even be more pronounced.  
In conclusion, a general and simple toxicokinetic model, adapted for three well known 
organic solvents, allowed us to show that metabolic parameters can have an important impact 
on the urinary levels of the corresponding biomarkers. These observations give evidence of an 
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interindividual variablity, an aspect that should have its place in the approaches for setting 
limits of occupational exposure. 
 
 
 
INTRODUCTION 
Toxicokinetic (TK) modeling is a useful tool to describe or predict the behavior of a 
chemical agent in the human or animal organism. Interest in it arose from the need to relate 
internal concentrations of active compounds with the external exposure conditions.
(1)
 Data-
based pharmacokinetic models were first developed in the 1920’s and several disciplines like 
inhalation anesthesia, chemical engineering, toxicology or computer sciences, contributed to 
their maturation throughout the last decades.
(2)
 Fiserova-Bergerova for example contributed 
intensively to the development of toxicokinetic models for inhaled organic solvents in 
humans.
(3-5) 
Depending on the substance, the complexity of the kinetics and the literature data 
available, two types of models can be used.
(6)
 Classical pharmacokinetic/toxicokinetic 
(PK/TK) models, represented by compartments within which the chemical is assumed to be 
homogeneously distributed, are suitable when limited toxicological data is available. Various 
data-dependent parameters, as for example the volume of distribution or the half-life, can be 
derived from the analysis of classical compartments models. They are limited from a 
structural point of view but can be used to make generalizations. Physiologically-based 
toxicokinetic (PBTK) models, which rely on the anatomical and physiological structure of the 
body, are preferred when the purpose is to know the substance’s concentration in different 
tissues or organs. They are more informative and usually allow for a better extrapolation 
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processes but they require a more intensive input data, which can raise more complex 
statistical issues.  
Several authors investigated the quantification of biological variability through TK/PBTK 
modeling. Droz et al.
(7)
, for example, developed a PBTK model for different workers under 
variable industrial environments while Pierrehumbert et al.
(8) 
tried to develop a general 
compartmental based TK model. The variability extent index and the main parameters 
affecting biological indicators were investigated by Truchon et al.
(9)
 while the impact of 
environmental variability was quantified by Berthet et al.
(10)
. Clewell et al.
(11)
 have described 
the contribution of age and sex to biological variability by developing a physiologically based 
pharmacokinetic model model to determine the tissue concentration as a function of time of 
some xenobiotics. 
The influence of sex on toxicokinetics may involve female-male differences in physical 
constitution (body water space, muscle mass, body fat, and blood flow), physiology 
(menopause and menstruation cycle), hormones (contraceptive pill) as well as metabolising 
enzymes (Löf et al., 1998).
(12) 
Although we can establish a list of contributing factors, as 
shown in a framework for sex differences by Gochfeld
(13)
, their relative importance is 
unknown for different chemicals of occupational interest.  
The aim of this study was to adapt an existing general toxicokinetic model to three organic 
solvents, which were methyl ethyl ketone (MEK), 1-methoxy-2-propanol (1M2P) and 1,1,1,-
trichloroethane (111TCE), and to take into account sex differences. The influence of sex on 
different biological indicators values had been evaluated in a previous human volunteer 
study
(14)
 by exposing volunteers to the three organic solvents mentioned above. Experimental 
data from that study was used to calibrate the present models. 
 
MATERIAL AND METHODS 
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Model description 
Pierrehumbert et al.
(8)
 have developed a compartmental based toxicokinetic model in order 
to quantify the effect of human variability on a wide range of biological exposure indicators. 
By applying it to four chemicals (toluene, phenol, lead and mercury), they showed its 
potential to be used for further substances. We actually underline this potential of the model 
by adapting it to three other compounds which are MEK, 1M2P and 111TCE.  
The general compartmentally based toxicokinetic model developed by Pierrehumbert et 
al.
(8)
 consists of four compartments and takes into account only absorption by inhalation.  The 
mass rate of chemical absorption into the central compartment from inhaled air is equal to the 
product of the chemical’s mass concentration in air, the alveolar ventilation rate scaled to 
body weight, and the fraction of the chemical absorbed by the lungs (pulmonary retention). 
The chemical is distributed between the central compartment and the peripheral one, or 
storage compartment. These compartments can be illustrated by different tissues, depending 
on the chemical. The distribution can be either flow or diffusion limited and includes the 
permeability and affinity of the tissue for the chemical. For transfer between central and 
peripheral compartments, mass rates are expressed as a function of blood flow, affinity and 
permeability. The metabolism, described with Michaelis–Menten kinetics, can give one or 
more metabolites, and can occur by serial or parallel metabolism. Elimination is represented 
by excretion in expired air, feces and urine, or by metabolism. For excretion, estimated mass 
rates are based either on the half-life of the chemical/metabolite, or on its clearance (e.g. bile 
flow for feces, urine flow for urine, alveolar ventilation for expired air) and volume of 
distribution. Mathematical equations describing the general model can be found in 
Pierrehumbert et al.
(8)
.  
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This general model was adapted to MEK, 1M2P and 111TCE using toxicokinetic data 
available in literature.
(15-21)
 The simulation software used for the development of the TK 
models was Berkeley Madonna (version 8.0.1.), developed by Robert Macey and George 
Oster of the University of California at Berkeley (USA). 
 
Model parameters 
     The group arithmetic means for weight, height and body fat were used in the model. 
Values for general physiological parameters like alveolar ventilation, cardiac output or organ 
blood flows corresponded to the values of a reference man. These were scaled in function of 
body weight. Otherwise, values were taken from literature, like partition coefficients or 
metabolic parameters.  
 
Sensitivity analysis 
Sensitivity analysis was performed in the same way as did Pierrehumbert et al.
(8)
 for 
determining the potential parameters with an important impact on the studied biological 
determinants. Changes in the model output values were calculated after increasing each initial 
toxicokinetic parameter value by 10 % for a given time. In this study, calculations were done 
for one time of interest, which was at the end of exposure (t=6).  
Likewise, the simulation software Berkeley Madonna also allowed to carry out a 
sensitivity analysis of a toxicokinetic model. Thus, this tool option was used in order to 
identify parameters of interest in the model during other time phases as for example during 
the elimination phase. 
 
Model analyses 
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The toxicokinetic models obtained for MEK, 1M2P and 111TCE were first calibrated with 
the experimental data obtained for these three solvents in a previous human volunteer 
study
(14)
.  
Briefly, in this previous study, controlled human exposures were carried out in a 12 m
3
 
exposure chamber for each solvent separately, during six hours and at half of the threshold 
limit value (TLV). The human volunteers groups were composed of ten young men and 
fifteen young women. The latter were separated into two sub-groups by taking into account 
the use or not of hormonal contraceptive. Following biological indicators of exposure were 
determined: urinary MEK, urinary 1M2P (conjugated and total), 111TCE in blood and in 
expired air, metabolites of 111TCE (trichloroethanol (TCOH) and trichloroacetic acid (TCA)) 
in urine. The corresponding biological exposure indices (BEIs) are summarized in Table I. 
Curve fitting has been performed with the software Berkeley Madonna, which can 
automatically find the values of one or more parameters in the model by minimizing the root-
mean-square between simulated and experimental data. The sensitivity analysis allowed the 
identification of the main parameters that could potentially influence the urinary 
concentrations of the studied biomarkers of exposure. These parameters were fitted to the 
experimental data obtained form the previous human volunteer study
(14)
.  
From these models, it is also possible to predict the concentration of the studied substances 
in other biological matrices, as for example in blood which corresponds to the concentration 
in the central compartment of the model. 
In a second step, calibrated models were used to evaluate their predictive ability, by 
simulating the concentration of the studied substances in other biological matrices, as for 
example in blood, or by changing the exposure conditions. Simulations were performed to 
mimic an occupational exposure at the TLV (8 h per day, 5 days per week, physical activity of 
50 W for 12 h per day and at rest for the remaining 12 hours).  
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Statistics 
A goodness-of-fit between experimental data and simulated data was assessed by 
calculating the percentage of model predictions that lie within the 95% confidence interval of 
each corresponding data point for each model and by linear regression analysis assuming that 
the slope yields the value of 1 in the case of perfect agreement. 
 
RESULTS 
 
Toxicokinetic models for MEK, 1M2P and 111TCE 
In most occupational exposure settings, the primary intake route for the three studied 
solvents is inhalation. The different compartmental TK models for the studied solvents, all 
metabolized via the cytochrome P450 mixed-function oxidase system, are illustrated on 
Figure 1. 
MEK is metabolized to 2,3-butanediol, 2-butanol and 3-hydroxy-2-butanone (major 
metabolite), all excreted in urine. A low fraction of unchanged solvent is excreted in the 
exhaled air. The urinary concentration of MEK at the end of the shift has been recommended 
as the most appropriate biological exposure indicator. MEK is nearly equally distributed 
between water and fat containing tissues.
(22)
 Thus the model is composed by a central 
compartment representing the total body water (TBW) and a peripheral compartment for the 
fatty tissues. 
1M2P belongs to the family of the propylene glycol ethers (PGE) which exists under the 
form of two isomers, alpha-isomer and beta-isomer. The latter one, considered as an impurity 
in commercial use, is first transformed into 2-alkoxy acetaldehydes by alcohol 
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dehydrogenases, and then into alkoxyacetic acids by aldehyde dehydrogenases, a toxic 
metabolite. Alpha-PGE are primarily metabolized to propylene glycol, carbon dioxide and 
glucuronide as well as sulfate conjugates of the parent compound. The urinary 1M2P 
concentration at the end of the shift is an appropriate biomarker. A central compartment 
equivalent to TBW and a second compartment illustrating the conjugation of 1M2P constitute 
the TK model for 1M2P. 
111TCE is metabolized to TCOH and TCA, both excreted in urine. Other minor 
metabolites (carbon dioxide, acetylene) are excreted in the exhaled air. The corresponding 
biological exposure indices are the urinary concentration of both metabolites and the blood 
concentrations of the parent compound and TCOH. The 111TCE concentration in the exhaled 
air can also be considered as a biomarker of exposure because the majority is excreted 
unchanged in the expired air and it can be measured several days after exposure due to its 
long half life in expired air. As the exposure scenarios were carried out during one day, 
urinary TCOH is the most appropriate biomarker for the model calibration with the 
experimental data. TCA concentrations are very low due to its long half life. Accumulation is 
possible during the week and thus,  it is not an appropriate biomarker for reflecting a daily 
exposure. Measurements of the indicators of exposure in blood or in expired air would be 
more suitable in the case of a chronic exposure to the chlorinated solvent. Consequently the 
TK model includes a central compartment equivalent to TBW, a peripheral one constituting 
the fatty tissues because of its high liposolubility, and a third compartment for the considered 
metabolite. 
The general physiological parameters used in the simulations are presented in Table II 
whereas the chemical specific parameters for each TK model are represented in Table III. 
 
Sensitivity analysis 
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The results of the sensitivity analysis, obtained after increasing each initial 
toxicokinetic parameter value by 10 % for a given time and summarized in Figure 2, showed 
that for the MEK model, urinary MEK concentration is especially sensitive to the metabolic 
parameters, the cardiac output and the liver blood flow. For the 1M2P model, the metabolic 
parameters and the cardiac output were identified to influence most the urinary 1M2P 
concentrations. Urinary metabolites values for 111TCE were mainly influenced by the 
metabolic parameters, the different partition coefficients and the TCOH urinary excretion rate. 
The sensitivity analysis carried out by the simulation software Berkeley Madonna 
indicated that for the MEK model, the partition coefficient between the central compartment 
and blood (at the beginning of the exposure as during the elimination phase) and the 
Michaelis-Menten maximum rate seemed to be  relevant parameters.  For the 1M2P model 
both Michaelis-Menten maximum rates, and for the 111TCE model the partition coefficient 
between the central compartment and air and the Michaelis-Menten maximum rate were 
influential. The exact values of the fitted parameters that have been identified by the 
sensitivity analysis are presented in Table III. 
 
Experimental data vs simulated data  
 
The percentage of model predictions that lies within the 95% confidence interval of each 
corresponding data point varies from 44.4 % to 87.5 % for the MEK model (44.4, 55.6 and 
87.5 % for the model fitted to the data obtained for men, for women with hormonal 
contraceptive and for women without hormonal contraceptive respectively), from 50 % to 90 
% for the 1M2P model (66.7, 80 and 50 % for the model fitted to the urinary free 1M2P data 
and 90, 72.7 and 55.6 % for the model fitted to the urinary total 1M2P obtained for men, for 
women with hormonal contraceptive and for women without hormonal contraceptive 
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respectively), and from 72.7 % to 88.9 % for the 111TCE model (80, 72.7 and 88.9 % for the 
model fitted to the data obtained for men, for women with hormonal contraceptive and for 
women without hormonal contraceptive respectively).   
Table IV summarizes the experimental data obtained at the end of exposure in the human 
volunteer study
(14)
 on one hand and the simulated values obtained at the end of exposure 
within the TK models on the other hand, for the considered biological determinants. Figures 3 
to 6 illustrate the comparison of experimental data with simulated data for the different 
urinary indicators of exposure considered. Data points on Figures 3 to 6 are arithmetic mean 
values ± SD (standard deviation). 
Regarding the goodness-of-fit between experimental data and simulated data, it can be 
assessed by linear regression analysis assuming that the slope yields the value of 1 in the case 
of perfect agreement. Thus a scatterplot of the predicted data versus the observed ones (see 
Figure 7) suggests that the toxicokinetic models seem adequate for the three studied 
substances, at least for the values obtained during exposure.  
The predictive ability of the model showed that in the case of 111TCE for example, the 
maximal blood concentration in each group of volunteers was equal to 0.28 mg/l, showing no 
differences between them. This observation can in fact be confirmed by the experimental data 
obtained in the previous human volunteer study
(14)
, where end-exposure values obtained for 
men, women with and without hormonal contraceptive, respectively were 362.97 (± 91.05), 
306.53 (± 152.27) and 371.13 (± 240.64) µg/l, with no statistically significant differences 
between the different groups.  
Predictive calculations were also done for estimating the urinary levels of the different 
biological biomarkers when workers were exposed during 8 hours per day, 5 days per week, 
at a 50 W work load, to the threshold limit value of each solvent studied. Results are 
illustrated in Figure 8 for each solvent and for each studied human volunteer group.  
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DISCUSSION 
Our results showed that it was possible to use an existing generic toxicokinetic model for 
other compounds by adapting it to three organic solvents. In fact, most of the simulation 
results showed good agreement with the experimental data obtained in a previous human 
volunteer study
(14)
..  
Regarding parameters that have been fitted in the three models, values indicate that 
differences between men and women can be explained by changes in metabolism, as  
suggested by a previous human volunteer study
(14)
. But the main conclusion of the latter one 
was that the differences observed between the human volunteers groups were due to an effect 
on the CYP2E1 activity by exogenous hormones. An analysis of variance in this study mainly 
showed an effect among women due to the use of hormonal contraceptive on the urinary 
levels of several biomarkers of exposure, with an increase of more than 50% in metabolites 
concentrations and a decrease of up to 50% in unchanged substances concentrations, 
suggesting an increase in their metabolism rate. This hypothesis can actually be confirmed 
with the obtained values when fitting the Michaelis-Menten maximum rates in the different 
models. The VM1 value for the group of women with hormonal contraceptive is 2.1, 2.3 and 
1.4 fold higher than the one for the group of women without hormonal contraceptive, in the 
MEK model, the 1M2P model and the 111TCE model respectively (see Table III notes). 
Concerning phase II metabolism, Miners et al.
(31)
 showed that glucuronidation was induced 
in women using oral contraceptives. In the previous human volunteer study
(14)
, women on 
hormonal contraceptives appeared to excrete a higher fraction as conjugate than those not 
taking hormonal contraception, indicating also that sex hormones levels may influence the 
enzyme activity of phase II reactions but differences were not statistically significant due to a 
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high variability. The VM2 value for the group of women with hormonal contraceptive is 2.5 
fold higher than the one for the group of women without hormonal contraceptive (see Table 
III notes). 
Physiological parameters are expressed in function of body weight and thus take into 
account possible male/female differences in pulmonary ventilation, cardiac output and organ 
blood flows, generally due to body size. Moreover the fact that differences are observed 
between women underlines Gochfeld’s hypothesis(13) that toxicokinetic differences mainly 
involve metabolism. The author also stated that there is still a tendency to believe that most 
sex differences relate to morphology and body size. He pointed out that the differences in 
susceptibility between men and women need to be incorporated in risk assessments, as most 
toxicological studies still focus on only one sex.  
The predictive simulations done over a week within working conditions indicated that 
exposure for women without hormonal contraceptive can be overestimated in the case of 
MEK and 1M2P but underestimated in the case of 111TCE. For the latter, Truchon et al.
(9)
 
have estimated the extent of the variability for its biomarkers, indicating that TCOH urinary 
levels can vary from 11 to 80 mg/l due to biological variability, without taking into account 
differences due to sex and age. Urinary TCOH concentrations measured in the previous 
human volunteer study
(14)
 are even lower, meaning that in this case, sex differences could 
contribute to enlarge the extent of the variability for the considered biological indicator. 
Moreover, the urinary levels in biomarkers predicted with our TK models were compared 
to the existing BEIs. Interestingly, urinary levels following TLV exposures to MEK and 
1M2P were found to be higher than the current BEI (see Figure 8), suggesting that work load 
can have a significant impact on biological exposure indicators.
(35) 
The poorest fit of the model to data occurred in the elimination phases of the urinary 
biomarkers of exposure, mainly for urinary MEK and urinary 1M2P (free and total). In fact 
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agreement between observed and predicted values is weaker and this can lead to an over- or 
underestimation of the corresponding exposure level. In the case of MEK, an explanation 
could be the metabolic saturation, as in humans it begins at relatively low levels of 
exposure
(18)
, and greater amounts of MEK would be expected to be excreted via the kidney. 
For 1M2P, the high variability in glucuronidation observed in the previous human volunteer 
study
(14)
 could explain the differences observed between experimental and simulated data. 
These observations give rise to some limitations of our general model. First equations 
describing Michaelis-Menten kinetics were simplified by assuming that saturation would not 
occur for the selected biomarkers of exposure in Pierrehumbert et al.
(8)
. Another limitation of 
the model is the fact that it takes into account only the absorption of the chemicals by 
inhalation. Skin absorption could be relevant for some solvents when exposed to the liquid 
form or to aerosols but less when exposed to the vapours.  
In conclusion, a general and simple toxicokinetic model, adapted for three well known 
organic solvents, allowed us to show that metabolic parameters can have an important impact 
on the urinary levels of the corresponding biomarkers. Indeed, experimental data from a 
previous study pointed out that for same exposure conditions, men and women can show a 
difference of 50 % among the urinary biological indicators levels. Moreover, when running 
the models by simulating industrial working conditions, these differences could be even more 
pronounced. These observations give evidence of an interindividual variability, an aspect that 
should have its place in the approaches for setting limits of occupational exposure. 
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FIGURE 1. Illustration of the different compartmental based TK models for (a) MEK, (b) 1M2P and (c) 
111TCE, with the black arrows indicating the biological determinants considered in this study, and with 
following flow rates air absorption (AA), air excretion (AE), urinary excretion (UE), metabolism (Met) and 
conjugation (Conj) expressed as [mg/h]. 
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FIGURE 2: Normalized sensitivity coefficients (NSC) for the various parameters used in the TK models 
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FIGURE 3. Comparison of experimental data with simulated data for urinary MEK obtained (a) in men and (b) 
in women. Urinary MEK concentrations as function of time were obtained after 6 hours of exposure to 99.15 ( 
5.29) ppm MEK. Data points are arithmetic mean values  SD (standard deviation); n = number of volunteers. 
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FIGURE 4. Comparison of experimental data with simulated data for urinary free 1M2P obtained (a) in men and 
(b) in women. Urinary free 1M2P concentrations as function of time were obtained after 6 hours of exposure to 
53.22 ( 3.04) ppm of 1M2P. Data points are arithmetic mean values  SD (standard deviation); n = number of 
volunteers. 
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FIGURE 5. Comparison of experimental data with simulated data for urinary total 1M2P obtained (a) in men and 
(b) in women. Urinary total 1M2P concentrations as function of time were obtained after 6 hours of exposure to 
53.22 ( 3.04) ppm of 1M2P. Data points are arithmetic mean values  SD (standard deviation); n = number of 
volunteers. 
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FIGURE 6. Comparison of experimental data with simulated data for urinary TCOH obtained (a) in men and (b) 
in women. Urinary TCOH concentrations as function of time were obtained after 6 hours of exposure to 102.55 
( 3.19) ppm of 111TCE. Data points are arithmetic mean values  SD (standard deviation); n = number of 
volunteers. 
 
 
24 
 
 
y = 0.9747x
R² = 0.9549
y = 1.0062x
R² = 0.8685
y = 0.9867x
R² = 0.9146
y = 0.9893x
R² = 0.9047
0
1
2
3
4
5
6
7
8
0 1 2 3 4 5 6 7 8
CMEK,urine [mg/l]
Cfree1M2P,urine [mg/l]
Ctotal1M2P,urine [mg/l]
CTCOH,urine [mg/g creatinine]
Experimental data 
S
im
u
la
te
d
 d
a
ta
 
FIGURE 7. Predicted data versus experimental data for the studied urinary biomarkers of exposure. Linear 
regression has been done for data obtained during the whole exposure scenario for each solvent.  
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FIGURE 8. Simulation of mean urinary levels of biological indicators of exposure in workers (by considering 
men, women with and without hormonal contraceptive) exposed during 8 hours per day, 5 days per week, at a 50 
W work load, to the threshold limit value of (a) MEK*, (b) 1M2P* and (c) 111TCE  
 
* The curve for men and the one for women with hormonal contraceptive are nearly overlapping. 
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TABLE I. Summary of the selected organic solvents and their corresponding urinary biomarkers of exposure, 
with the existing occupational exposure limit values and biological exposure indices for different countries 
(USA, Germany, Switzerland) 
 
   
Biological determinant TLV
*
/MAK
**
/VME
***
  BEI
*
/BAT
**
/VBT
***
 
  (ppm) 
urine  
(mg/l) 
blood  
(g/l) 
expired air  
(ppm) 
Methyl ethyl ketone (MEK) 200/200/200 2
a
/5
a
/5
a
 
  
        
1-Methoxy-2-propanol (1M2P) 100/100/100 -/15
a
/20
a
   
        
1,1,1-Trichloroethane (111TCE) 350/200/200  - 
-
/550
b,c
/550
b,c
 
40
b,c
/-/- 
Trichloroethanol (TCOH)   30
a,b
/-/-  1000
a,b
/-/-  
Trichloroacetic acid (TCA)   10
b
/-/-   
 
 
*
 The American Conference of Industrial Hygienists (ACGIH) sets threshold limit values (TLV) and 
biological exposure indices (BEI). 
 
**
  The German Research Foundation (Deutsche Forschungsgemeinschaft - DFG) sets “Maximale 
Arbeitsplatz-Konzentrationen”  (MAK) and “Biologische Arbeitsstoff-Toleranzen” (BAT). 
 
***
 The Swiss National Accident Insurance Fund (Schweizerische Unfallversicherungsanstalt - Caisse nationale 
suisse d'assurance en cas d'accidents - Istituto nazionale svizzero di assicurazione contro gli infortuni – 
(SUVA) sets “valeurs (limites) moyennes d’exposition” (VME) and “valeurs biologiques tolérables” 
(VBT). 
 
a
 ES: end of shift  
b
 EW: end of week  
c
 PS: prior to shift 
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TABLE II. General physiological parameters used for the TK models. Arithmetic mean values (±SD: standard 
deviation) are indicated for body weight, body height and body fat; n = number of volunteers. 
 
Parameters Symbol At rest/50 W 
Body weight [kg] 
 
 
Body height  [cm] 
BW 
 
 
BH 
 
70.7 ± 10.3 for men (n=10) 
60.1 ± 7.2 for women with hormonal contraceptive (n=10) 
65.6 ± 11.2 for women without hormonal contraceptive (n=5) 
177.5 ± 3.2 for men (n=10) 
167 ± 3.8 for women with hormonal contraceptive (n=10) 
163.4 ± 2.3 for women without hormonal contraceptive (n=5) 
Body fat [% of BW] 
 
 
Lean body mass [kg] 
 
Total body water [kg] 
bf 
 
 
LBM 
 
TBW 
11.3 ± 5.2 for men (n=10) 
19.8 ± 4.6 for women with hormonal contraceptive (n=10) 
26.6 ± 8.9 for women without hormonal contraceptive (n=5) 
LBM = BW – BFawith BF = bf * BW/100For a man : -12.86 
+ 0.1757 * BH + 0.3331 * BW a 
  For a woman : -2.097 + 0.1069 * BH + 0.2466 * BWa 
Cardiac output [l/(h*kg0.7)] 
Alveolar ventilation [l/(h*kg0.7)] 
Urinary excretion rate [ml/(h*kg0.82)] 
Creatinine excretion rate [mol/(h*kg0.9)] 
Qc 
Valv 
kur 
kcr 
18.0b at rest/30.8b at 50 W 
18.0b at rest/2.1951*Qc
b at 50 W 
1.848c 
12.06c 
 
a Fiserova-Bergerova(23) 
b Thomas et al.(24) 
c Laparé et al.(25) 
 
 
TABLE III. Chemical specific parameters used for the TK models 
 
Parameters Symbol At rest/50 W 
MEK 
Threshold limit value [mg/m3] 
Molecular weight [g/mol] 
Exposure concentration [mg/m3] 
 
TLV 
MW 
Cexp 
 
590 
72 
282.9 
Pulmonary retention [-] Rpulm 0.558
a 
Volume of the central compartment expressed as a fraction of BW [-] 
Volume of the peripheral compartment expressed as a fraction of BW [-] 
Fraction of cardiac output in the peripheral compartment [-] 
Fraction of cardiac output in metabolism [-] 
Blood/air partition coefficient [-] 
Central/blood partition coefficient* [-] 
Peripheral/central partition coefficient [-] 
Metabolism 
Michaelis-Menten maximum rate* [mg/(h*kg0.75)]  
Michaelis-Menten constant [mg/l] 
FVc 
FVp 
BFp 
BF1 
Pblood_air 
Pc_blood 
Pp_c 
 
VM1 
KM1 
1*TBW/BW 
1*BF/BW 
0.06b/0.05b 
0.26b/0.16b 
125a 
0.856a 
1.296a 
 
5.44c 
0.63c 
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1M2P 
Threshold limit value [mg/m3] 
Molecular weight [g/mol] 
Exposure concentration [mg/m3] 
Pulmonary retention [-] 
Volume of the central compartment expressed as a fraction of BW [-] 
Fraction of cardiac output in metabolism [-] 
Blood/air partition coefficient [-] 
Central/blood partition coefficient [-] 
Metabolism 
Michaelis-Menten maximum rate** [mg/(h*kg0.75)]  
Michaelis-Menten constant* [mg/l] 
Conjugation 
Michaelis-Menten maximum rate** [mg/(h*kg0.75)]  
Michaelis-Menten constant [mg/l] 
Urinary excretion rate for conjugated 1M2P [h-1] 
 
111TCE 
Threshold limit value [mg/m3] 
Molecular weight [g/mol] 
Molecular weight of metabolite [g/mol] 
Molecular weight of creatinine [g/mol] 
Exposure concentration [mg/l] 
Pulmonary retention [-] 
Volume of the central compartment expressed as a fraction of BW [-] 
Volume of the peripheral compartment expressed as a fraction of BW [-] 
Volume of the metabolite compartment expressed as a fraction of BW [-] 
Fraction of cardiac output in peripheral compartment [-] 
Fraction of cardiac output in metabolite compartment [-] 
Blood/air partition coefficient [-] 
Central/air partition coefficient*** [-] 
Peripheral/air partition coefficient [-] 
Metabolite/air partition coefficient [-] 
Metabolism 
Michaelis-Menten maximum rate*** [mg/(h*kg0.75)]  
Michaelis-Menten constant [mg/l] 
Metabolic rate TCOH  TCA [1/(h*kg-0.3)] 
Excretion 
TCOH urinary excretion rate [1/(h*kg-0.3)] 
 
 
TLV 
MW 
Cexp 
Rpulm 
FVc 
BF1 
Pblood_air 
Pc_blood 
 
VM1 
KM1 
 
VM2 
KM2 
kconj 
 
 
TLV 
MW 
MW1 
MWcr 
Cexp 
Rpulm 
FVc 
FVp 
FV1 
BFp 
BF1 
Pblood_air 
Pc_air 
Pp_air 
PM1_air 
 
VM1 
KM1 
kM1_M2 
 
ku1 
 
 
360 
90.12 
177.1 
0.9d 
1*TBW/BW 
0.26b/0.16b 
12383e 
12280e 
 
22f 
45f 
 
0.2f 
80f 
0.2d 
 
 
1080 
133.40 
149.40 
113.12 
545.6 
0.25g 
1*TBW/BW 
1*BF/BW 
0.026h 
0.06b/0.05b 
0.26b/0.16b 
2.53i 
2.53i 
263i 
8.6i 
 
0.42i 
5.75i 
0.069j 
 
 
0.093j 
 
a Liira et al.(22) 
b Thomas et al.(24) 
c Thrall et al.(19) 
d   Devanthéry(26) 
e    Johanson et al.(27) 
f  Corley et al.(20) 
29 
 
g  Nolan et al.(28) 
h Tardif et al.(29) 
i  Reitz et al.(15) 
j  Caperos et al.(30) 
 
* For the MEK model, fitted parameters with their corresponding values are following:  
- Pc_blood = 2.106, 2.817 and 2.662 for men, women with hormonal contraceptive and women without 
hormonal contraceptive respectively ; 
- VM1 = 2.13, 1.80 and 0.86 mg/l for men, women with hormonal contraceptive and women without 
hormonal contraceptive respectively. 
** For the 1M2P model, fitted parameters with their corresponding values are following: 
- VM1 = 35.94, 44.56 and 19.37 mg/(h*kg
0.75) for men, women with hormonal contraceptive and 
women without hormonal contraceptive respectively ; 
- VM2 = 0.09, 0.15 and 0.06 mg/(h*kg
0.75) for men, women with hormonal contraceptive and women 
without hormonal contraceptive respectively. 
*** For the 111TCE model, fitted parameters with their corresponding values are following: 
- Pc_air = 7.28, 4.74 and 4.00 for men, women with hormonal contraceptive and women without 
hormonal contraceptive respectively ; 
- VM1 = 0.13, 0.24 and 0.17 mg/(h*kg
0.75) for men, women with hormonal contraceptive and women 
without hormonal contraceptive respectively. 
 
TABLE IV. Summary of the different biomarkers values (experimental and simulated) obtained at the end of 
exposure. Arithmetic mean values ( SD: standard deviation) are indicated for experimental data.  
 
 Biological indicators levels at the end of exposure 
 
CMEK,urine  
[mg/l] 
Cfree1M2P,urine  
[mg/l] 
Ctotal1M2P,urine  
[mg/l] 
CTCOH,urine  
[mg/g creatinine] 
Men 
    
   Experiment 1.00 ± 0.13 2.99 ± 0.49 4.36 ± 1.76 5.42 ± 2.19 
Simulation 1.12 3.15 3.91 5.68 
 
Women with hormonal contraceptive 
    
Experiment 0.97 ± 0.23 2.61 ± 0.96 4.17 ± 1.58 6.46 ± 1.73 
Simulation 1.13 2.86 4.09 6.54 
 
Women without hormonal contraceptive 
    
Experiment 1.44 ± 0.76 3.81 ± 1.68 4.85 ± 0.97 3.77 ± 1.24 
Simulation  1.51 4.89 5.64 3.69 
 
